Performance in Delivering Report Qtr 3 Oct- Dec 2018

MREC Number	IRAS Number	Project Short title	Project Full title	Project type	Project site target participants	Project site planned recruitment end date	Project site actual recruitment end date	Recruited (total)	PII/D Study - Intervention	PII/D Comment
17/LO/0794	223700	RHCF	A 52-week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis who are Biologic Disease-Modifying Anti-Rheumatic Drug Naive	Commercial portfolio	2	30/04/2018	24/05/2018	2	Drug	Pharmacy staffing & IMP label delays. Staff training delay also.
16/EM/0384	182787	BMS Augustus	An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention	Commercial portfolio	6	31/05/2018	10/04/2018	1	Drug	delay due to Dr Barr not completing GCP refresher. 09/01/2018 green light received from sponsor to commence recruitment.
17/LO/1147	222154	Tralokinumab in moderate-severe AD - 1326	Tralokinumab monotherapy for moderate-to-severe atopic dermatitis ECZTRA 2 (ECZema TRAlokinumab trial no. 2)	Commercial portfolio	6	31/05/2018	26/04/2018	7	Drug	
18/YH/0012	237184	ECZTRA 3 (ECZema TRAlokinumab trial no. 3)	Tralokinumab in combination with topical corticosteroids for moderate-to-severe atopic dermatitis. ECZTRA 3 (ECZema TRAlokinumab trial no. 3)	Commercial portfolio	6	18/08/2018	12/10/2018	4	Drug	
16/EM/0194	194984	DERM 5311	Effectiveness of an image analysing algorithm to diagnose melanoma compared to gold standard histological determination	Commercial portfolio	23	30/09/2018	29/06/2018	23	Device	HRA confirmation of site added recieved 19.09.17
16/EM/0193	190690	CARD 4843	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The Dal-GenE trial	Commercial portfolio	6	31/10/2018	12/11/2018	7	Drug	
18/SC/0210	239572	EFFICACY AND SAFETY OF PF-04965842 200 MG AND 100 MG QD MONOTHERAPY IN SUBJECTS WITH AD	A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 200 MG AND 100 MG QD MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND ABOVE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS (AD)	Commercial portfolio	1	26/11/2018	26/11/2018	0	Drug	delays in set-up due to pharmacy staff shortage and sponsor not completing IT & PPQ forms for equipment. Also sponsor delays as awaiting EC confirmation to approve extension study - B7451015. 18/10/2018 IIP approval received by sponsor.
17/EE/0079	220827	CL010_168	A Randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamise/ Azathioprine	Commercial portfolio	2	31/12/2018	04/07/2018	0	Drug	CTA signed, sponsor & study team unable to perform SIV until 28/07/2017. Due to PI on annual leave, recruitment to commence 04/09/17. Excluded from time to target as rare disease.
16/LO/1822	212944	CARD 5650	A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction (HFrEF) - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction (VICTORIA)	Commercial portfolio	10	31/12/2018	31/12/2018	11	Drug	